R x only. See additional information. The total 24-hour dose should not generally exceed 200 mEq of potassium. Administration rates above 20mmol/hour require cardiac monitoring. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. (See WARNINGS and PRECAUTIONS.).
port and inject.
Such use You are encouraged to report negative side effects of prescription drugs to the FDA. Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus. For The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion. Flexible Plastic Container. completed. Protect from freezing. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Because many drugs are excreted in human milk, caution should be exercised when Potassium Chloride in Sodium Chloride Injection, USP is administered to a nursing mother. electrolyte concentrations, overhydration, congested states or pulmonary edema. The concentration of potassium for intravenous administration via a peripheral line should not exceed 40mmol/L, as higher strengths can cause phlebitis and pain. Primary admixture - 'Ready-to-use' KCL 20 meq/100ml - Floors and ICU: Ready-to-use, solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single dose container for intravenous administration.20 mEq/100 mL: Osmolarity: 400 mOsmol/L [Peripheral line may be used - Monitor for pain during the infusion and adjust rate if needed.] Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. The risk of dilutional states is inversely proportional to the electrolyte concentrations Complete information is not available. Potassium chloride + Glucose + Sodium chloride. A deficiency of either potassium or chloride will lead to a deficit of the other. Parenteral drug products should be inspected visually for particulate matter If leaks are found, discard solution as sterility may be impaired. Tear overwrap down side at slit and remove solution container. POTASSIUM 24 mEq; SODIUM 130 mEq; CHLORIDE Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Evacuate both ports by squeezing them while container is in the upright Intravenous solution with potassium chloride (I.V. The intravenous administration of Potassium Chloride in Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
Consult with pharmacist, if available. Heavier shading indicates greater network coverage, Learn more about the RMOCs, view recommendations and resources, and raise a topic. Potassium Chloride in Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Caution must be exercised in the administration of Potassium Chloride in Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. Attach administration set. The opacity will diminish gradually. Potassium Chloride in Sodium Chloride Injection, USP is a sterile, nonpyrogenic, solution for fluid and electrolyte replenishment in a single dose container for intravenous administration.
Avoid excessive heat. compatible via Y site injection with hydrocortisone, potassium chloride, and vitamin B complex with C diltiazem compatible via Y-site with amiodarone, ampicillin, calcium Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.
If supplemental medication is desired, follow directions below before preparing for administration. Solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. Those additives known to be incompatible should not be used.